Characterizing Population Differences between Clinical Trial and Real World Populations
Characterizing Population Differences between Clinical Trial and Real World Populations
批准号:
10341133
负责人:
Brett K Beaulieu-Jones
金额:
$6.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-02-15 至 2022-11-01
关键词:
AffectAgeAge of OnsetAreaAutomobile DrivingAwardBiologicalCaringClinicalClinical DataClinical TrialsCodeComplexComputerized Medical RecordDataData SetData SourcesDevelopmentDimensionsDiseaseDrug ApprovalEffectivenessEligibility DeterminationEnsureEpilepsyEstrogensEthnic OriginExhibitsFoundationsFutureGaitGenesGeneticGeographyGoalsGoldGuidelinesHealthcareHeterogeneityHormonalHospitalsIndividualInformaticsInsuranceInterventionMachine LearningMeasuresMenarcheMenopauseMentorsMethodologyMethodsModernizationMutationNeurologicNeurologyParkinson DiseaseParticipantPatientsPerformancePerimenopausePerinatalPharmaceutical PreparationsPhysiologyPlacebosPoliciesPolypharmacyPopulationPositioning AttributePregnancyPriceProceduresRandomizedRandomized Controlled TrialsRare DiseasesResearchResearch PersonnelSafetyScienceSeizuresSocioeconomic StatusSubgroupSymptomsTarget PopulationsTestingTherapeutic EffectTrainingTreatment EfficacyTremorUnderrepresented PopulationsValidationWomanarmbasebirth controlcostdisease diagnosisdisorder subtypedisparity reductioneffectiveness analysisefficacy clinical trialglucosylceramidasehealth care disparityinclusion criteriainterestmembermultiple data sourcesoncology trialpatient populationreproductivesexsocioeconomic diversitystandard measurestandard of carestatisticssuccesstherapeutic developmenttreatment effecttrial comparingunethical
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Randomized controlled trials are the gold standard for measuring the effect of a treatment or intervention. Unfortunately, it is not feasible to conduct a randomized controlled trial to test all research questions, whether due to cost, achieving sufficient subject sizes or when administering an arm of the trial would be unethical. To understand the effects of therapeutics, policy changes, and other interventions where it is not possible to administer a clinical trial, researchers have developed approaches that attempt to simulate clinical trials in observational data. Despite sophisticated statistical methodologies, it is not clear whether it is possible to reliably simulate a randomized controlled in observational data. We aim to quantify one potential driver of these different results, differences between the clinical trial and real-world populations. In Aim 1, we compare trials that have individual level data available to three real- world data sources. In Aim 2, we develop methodologies to infer most likely individual-level statistics from aggregate trial statistics using real world data. Finally, in Aim 3 we compare neurological trials that do not release individual level data to real world data. We then estimate the transportability of treatment estimates across different populations including: the population eligible for the trial in RWD and the population ineligible for the trial but receiving the treatment in RWD. This allows for the study of indication drift and treatment heterogeneity. By uncovering differences between these groups, we may be able to identify groups that are underrepresented in clinical trials to help reduce healthcare disparities. The K99/R00 award will allow me to gain expertise in using regulatory sciences (with mentor Dr. Florence Bourgeois and advisor Dr. Deborah Schrag) for biologic discovery (with mentors Dr. Tianxi Cai and Dr. Isaac Kohane) within neurology (with mentors Dr. Page Pennell and Dr. Clemens Scherzer). My background in statistics, informatics, genetics, and machine learning with clinical data sources ideally positions me for the proposed project. The proposed training plan, mentoring and project will provide a strong foundation for a successful transition to independent research.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/s2589-7500(23)00179-6
发表时间:
2023-12
期刊:
LANCET DIGITAL HEALTH
影响因子:
30.8
作者:
[Beaulieu-Jones, Brett K., Villamar, Mauricio F., Scordis, Phil, Bartmann, Ana Paula, Ali, Waqar, Wissel, Benjamin, Alsentzer, Emily, de Jong, Johann, Patra, Arijit, Kohane, Isaac]
通讯作者:
Kohane, Isaac
Characterizing Population Differences between Clinical Trial and Real World Populations
-
批准号:10703711
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2023
-
负责人:Brett K Beaulieu-Jones
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: